Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    SpaceX shareholders approve 5-for-1 stock split , Bloomberg News reports

    May 16, 2026

    US hantavirus case was false positive; outbreak cases drop from 11 to 10

    May 16, 2026

    Kettering MP resigns from Department of Health job

    May 16, 2026
    Facebook X (Twitter) Instagram
    Addison Markets
    • Home
    • USA
    • Europe
    • Business
    • Investing
    • Tech
    • Politics
    • Contact Us
    Addison Markets
    Home»Business»FDA shuffles top drug, biologics leaders in latest leadership shakeup
    Business

    FDA shuffles top drug, biologics leaders in latest leadership shakeup

    franperez66q@protonmail.comBy franperez66q@protonmail.comMay 16, 2026No Comments2 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email


    The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, April 22, 2025.

    Nathan Posner | Anadolu | Getty Images

    The U.S. Food and Drug Administration is shuffling its top drug and biologics regulators, according to a memo seen by CNBC, days after the departure of former commissioner Marty Makary.

    Acting director of the FDA’s Center for Drug Evaluation and Research Tracy Beth Høeg and acting director of the Center for Biologics Evaluation and Research Katherine Szarama will leave their roles, according to the memo. The two divisions are responsible for regulating prescription drugs, including pills and vaccines.

    Szarama will remain at the agency, according to the memo. Høeg in a post on X said she was fired. Michael Davis will replace Høeg at CDER and Karim Mikhail will replace Szarama at CBER. Lowell Zeta will take over as acting chief of staff. As of Friday night, an organization chart on the the FDA’s website had been updated to reflect those changes.

    The shake up caps a tumultuous week at the FDA, which is responsible for regulating products that account for some 20% of consumer spending in the U.S. Makary resigned after days of reports that President Donald Trump wanted to oust the commissioner. And it’s the latest shuffle at an agency that’s struggled with turnover under the second Trump administration.

    Davis becomes one of several people to lead CDER since last January. CBER has also seen multiple faces in the job over the past year, including Vinay Prasad, who left the division then returned only to leave again after a series of controversies.

    The Trump administration hopes to name a new nominee for permanent commissioner in a matter of weeks, the senior administration official told CNBC this week. That person would need to be confirmed by the Senate. Meanwhile, the Trump administration is trying to fill health vacancies, including the director for the Centers for Disease Control and Prevention and the surgeon general.

    Correction: Michael Davis will replace Høeg at CDER and Karim Mikhail will replace Szarama at CBER. A previous version incorrectly identified their roles.

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    franperez66q@protonmail.com
    • Website

    Related Posts

    What’s ahead: Wall Street and Main Street face off with Nvidia, consumer earnings

    May 16, 2026

    FAA cuts target for air traffic control staffing

    May 16, 2026

    Sundheim’s D1 Capital bought several tech stocks last quarter — with one big exception

    May 16, 2026

    Jim Cramer fears SpaceX’s IPO could be ‘destructive’ for the rest of market

    May 15, 2026

    David Tepper’s Appaloosa nearly doubles Amazon stake in Q1, adds Sandisk

    May 15, 2026

    AI chip bubble is now bigger than the Nasdaq during dot-com frenzy

    May 15, 2026
    Leave A Reply Cancel Reply

    Top Reviews
    Editors Picks

    SpaceX shareholders approve 5-for-1 stock split , Bloomberg News reports

    May 16, 2026

    US hantavirus case was false positive; outbreak cases drop from 11 to 10

    May 16, 2026

    Kettering MP resigns from Department of Health job

    May 16, 2026

    What’s ahead: Wall Street and Main Street face off with Nvidia, consumer earnings

    May 16, 2026
    © 2026 All right reserved
    • Privacy Policy
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.